

Self-reporting of medications in sexual assault patients across time

Buchanan, J⁸, Bucossi M⁸, Metz M⁸, Maslen S⁸, Sullivan J^{1,2}, Maltez B^{1,2}, Bhatt K^{1,2}, Soward A^{1,2}, D'Anza T⁴, Bell K⁵, Lechner M⁶, Reese R⁷, Ho J⁹, Rossi C¹⁰, Black J¹¹, Reed G¹², Platt M¹³, Riviello R¹⁴, Nouhan P¹⁵, Phillips C¹⁶, McLean SA^{1,2,3}

From the ¹Institute for Trauma Recovery; ²Department of Anesthesiology, University of North Carolina, Chapel Hill, NC; ³Department of Emergency Medicine, University of North Carolina, Chapel Hill, NC; ⁴SANE Program, Albuquerque SANE Collaborative, Albuquerque, NM; ⁵SANE Program, Tulsa Forensic Nursing Services, Tulsa, OK; ⁶SANE Program, UHealth, Colorado Springs, CO; ⁷SANE Program, Crisis Center of Birmingham, Birmingham, AL; ⁸SANE Program, Denver Health, Denver, CO; ⁹SANE Program, Hennepin County Medical Center, Minneapolis, MN; ¹⁰SANE Program, Cone Health, Greensboro, NC; ¹¹SANE Program Austin SAFE Alliance, Austin, TX; ¹²SANE Program Christiana Care, Newark, DE; ¹³SANE Program, Kentucky One Health- University of Louisville Hospital, Louisville, KY; ¹⁴SANE Program, Drexel University College of Medicine, Philadelphia, PA; ¹⁵SANE Program Wayne County SAFE, Detroit, MI; ¹⁶SANE Program, MedStar Health, Washington, DC



BACKGROUND

- A paucity of literature exists describing the self-reporting of medications used by sexual assault (SA) patients.
- Medication use prior to assault, one week after, and at six week follow-up were analyzed.

OBJECTIVES

- Provide descriptive data from an on-going NIH-funded study to examine the medications used by SA patients across time.

METHODS

- Secondary analysis of data collected from 6/2015 – 3/2017 as part of an on-going NIH-funded trial evaluating the mechanisms of chronic musculoskeletal pain following SA
- 13 emergency department & clinical-based SA programs across the U.S.
- Female survivors ≥18 who presented within 72 hours of assault, received a SANE exam, & who meet other inclusion criteria were eligible. Subjects completed a self-report assessment at time of exam & assessments at 1 week, 6 week, 6 month & 12 months.

LIMITATIONS

- Limitations include the self-reporting nature of this study, lack of validation of agents by conformational screening, limited follow-up & exclusion on non-English speaking patients.

CONCLUSIONS

- First multi-site comparison of medication use prior to & following SA.
- OTC medication use increased in the weeks following SA.
- Psychotropic agents significantly increased at 1 week and 6 weeks.
- Prescription medication use decreased at all time points, likely related to lack of follow-up.
- OTC medication use significantly changed from pre to post assault & significantly increased over time after assault.
- These results suggest that the medication needs of sexual assault survivors evolve in the subsequent weeks after an assault.

RESULTS

Prevalence of medication use prior to and post-sexual assault.

Classification	Prevalence prior to assault (%) n = 344	Prevalence 1 week post assault (%) n = 429	Prevalence 6 weeks post assault (%) n = 277	Prior / 1 week p value	Prior / 6 week p value	1 week / 6 week p value
Over-the counter (OTC)	25%	30%	37%	0.123	0.001***	0.053 ^t
Herbal	2%	2%	3%	1	0.423	0.396
Prescription	31%	24%	15%	0.03*	0.0001***	0.0038**
Benzodiazepines, opioids, muscle relaxants	13%	14%	15%	0.687	0.474	0.712
Psychotropic	22%	15%	22%	0.012*	1	0.018*

